• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Dr Marcus H. Snow: The US Launch of Renflexis

Video

Marcus H. Snow, MD, Assistant Professor Rheumatology, University of Nebraska, discusses the recent launch of a new biosimilar infliximab, Renflexis, in the United States.

Transcript:

What are your thoughts on the recent launch of Renflexis in the United States?

I think that it will be very interesting to see what happens now that we have 3 versions of infliximab on the market. Will this drive the cost down? I think that it remains to be seen. I think, as you look at what has happened since the first biosimilar for infliximab has hit the market, you have seen insurance companies—United, for example, actually signed a contract with Remicade to stay with the bio-originator. I think you are going to see some of this, but I think it will be interesting to see the uptake and how this happens, and I think we will start to see the outcomes of this moving forward.

Recent Videos
Canavan & O’Dell
Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health.
Elena Wolff-Holz, MD.
Elena Wolff-Holz, MD, global head of clinical development at Biocon Biologics
Elena Wolff-Holz, MD
Travis Brewer, Texas Oncology
Josh Canavan, PharmD, head of pharmacy at RazorMetrics
Tiago Biachi, MD, PhD
Elie Bahou, MD, PhD
Steve Pickette, PharmD
Related Content
© 2025 MJH Life Sciences

All rights reserved.